Merck jumps after CHMP backs Keytruda plus Padcev for certain bladder cancer patients, a combo with the potential to expand ...
Merck is racing to defend its leadership in the market for cancer drugs ahead of Keytruda’s looming patent cliff. A clinical ...
The news adds two concrete pillars to the Keytruda “patent wall”: (1) Phase 3 OptiTROP-Lung05 shows Keytruda + sac-TMT beats ...
Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was “significantly ...
Merck-Kelun ADC outperforms Keytruda in trial, a closely watched Parkinson’s drug fails, and more biotech news from The ...
Merck (MRK) stock gains as a cancer drug the company develops with Kelun-Biotech bests its Keytruda blockbuster in a ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive ...
Professional antigen-presenting cells—monocytes and macrophages—engulf these proteins, digest them into short peptide ...
Though the Tecentriq SC has created buzz, oncologists say it is not about speed. It reflects how cancer care is evolving from ...
The late-stage miss shakes analyst confidence in Regeneron’s clinical execution, according to BMO Capital Markets, also ...
TuHURA Biosciences, Inc. (NASDAQ: HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics ...
Discusses Extended Follow-Up Data From Phase 3 Trial of aglatimagene besadenovec in Localized Prostate Cancer May 15, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results